Scarica l'app Stockscreener
25.86
0.78%
0.20
Dopo l'orario di chiusura:
25.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$25.66
Aprire:
$25.44
Volume 24 ore:
2.76M
Relative Volume:
3.29
Capitalizzazione di mercato:
$3.80B
Reddito:
-
Utile/perdita netta:
$-323.01M
Rapporto P/E:
-13.40
EPS:
-1.93
Flusso di cassa netto:
$-272.30M
1 W Prestazione:
-1.60%
1M Prestazione:
-1.18%
6M Prestazione:
-5.24%
1 anno Prestazione:
-28.52%
Intervallo 1D:
$25.25
$26.27
Intervallo di 1 settimana:
$25.25
$28.08
Portata 52W:
$24.61
$45.58
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
25.86 | 3.80B | 0 | -323.01M | -272.30M | -2.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Wells Fargo & Company Issues Pessimistic Forecast for Immunovant (NASDAQ:IMVT) Stock Price - Defense World
Wells Fargo & Company Lowers Immunovant (NASDAQ:IMVT) Price Target to $45.00 - MarketBeat
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.89 Consensus Target Price from Analysts - MarketBeat
Immunovant (NASDAQ:IMVT) Shares Down 5.2%Should You Sell? - MarketBeat
Immunovant's SWOT analysis: biotech stock poised for growth in Graves' disease - Investing.com India
State Street Corp Buys 303,386 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Head to Head Contrast: Jasper Therapeutics (NASDAQ:JSPR) versus Immunovant (NASDAQ:IMVT) - Defense World
The Manufacturers Life Insurance Company Has $1.05 Million Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Charles Schwab Investment Management Inc. Has $15.75 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Redmile Group LLC Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Immunovant's SWOT analysis: stock undervalued amid promising Graves' disease treatment - Investing.com UK
Immunovant director Atul Pande sells shares for $221,185 By Investing.com - Investing.com Canada
Immunovant director Atul Pande sells shares for $221,185 - Investing.com
(IMVT) Investment Analysis and Advice - Stock Traders Daily
Bamco Inc. NY Sells 25,000 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Erste Asset Management GmbH Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Baker BROS. Advisors LP Raises Holdings in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Fmr LLC Increases Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Intech Investment Management LLC Buys Shares of 21,825 Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Algert Global LLC Sells 83,969 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Contrasting Immunovant (NASDAQ:IMVT) and enGene (NASDAQ:ENGN) - Defense World
Immunovant, Inc. (NASDAQ:IMVT) Receives $48.10 Average Target Price from Analysts - Defense World
Have Immunovant Insiders Been Selling Stock? - Simply Wall St
Immunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Buy" by Brokerages - MarketBeat
KBC Group NV Purchases 612 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World
Connor Clark & Lunn Investment Management Ltd. Sells 56,789 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Trend Tracker for (IMVT) - Stock Traders Daily
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $106,228.30 in Stock - MarketBeat
Insider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells 16,692 Shares of Stock - MarketBeat
Immunovant CEO Peter Salzmann sells shares for $424,811 By Investing.com - Investing.com South Africa
Immunovant CFO Eva Renee Barnett sells $106,228 in stock By Investing.com - Investing.com South Africa
Immunovant CEO Peter Salzmann sells shares for $424,811 - Investing.com
Immunovant CFO Eva Renee Barnett sells $106,228 in stock - Investing.com
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Victory Capital Management Inc. - Defense World
Victory Capital Management Inc. Has $9.56 Million Stake in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
Why Is Immunovant, Inc. (IMVT) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock hits 52-week low at $24.66 amid market shifts - Investing.com Nigeria
Principal Financial Group Inc. Purchases 391,436 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat
(IMVT) Technical Data - Stock Traders Daily
FMR LLC's Strategic Acquisition of Immunovant Inc Shares - GuruFocus.com
Immunovant: Pipeline Progressing With One Minor Delay (NASDAQ:IMVT) - Seeking Alpha
Immunovant (NASDAQ:IMVT) Posts Earnings Results, Misses Expectations By $0.15 EPS - MarketBeat
Analysts Provide An Important Insights On Immunovant Inc (IMVT) - Stocks Register
Immunovant’s Strategic Advances in Autoimmune Therapies - TipRanks
Interesting IMVT Put And Call Options For March 2025 - Nasdaq
Immunovant's (IMVT) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immunovant Inc Azioni (IMVT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hughes Douglas J. | Director |
Dec 02 '24 |
Sale |
28.54 |
5,425 |
154,830 |
119,585 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):